505 POSTER Preliminary results of a phase II clinical trial of the anti EGFR monoclonal antibody Nimotuzumab in combination with whole brain radiation therapy in patients diagnosed with advanced non-small cell lung cancer tumors unresectable brain metastases

A.Macias; E.Neninger; E.Santiesteban; J.Figueredo; A.Hernandez; F.Aguirre; N.Aguilera; T.Crombet

首页> 外文期刊>European Journal of Cancer Supplements >505 POSTER Preliminary results of a phase II clinical trial of the anti EGFR monoclonal antibody Nimotuzumab in combination with whole brain radiation therapy in patients diagnosed with advanced non-small cell lung cancer tumors unresectable brain metastases

【24h】

505 POSTER Preliminary results of a phase II clinical trial of the anti EGFR monoclonal antibody Nimotuzumab in combination with whole brain radiation therapy in patients diagnosed with advanced non-small cell lung cancer tumors unresectable brain metastases

机译：505 POSTER抗EGFR单克隆抗体尼莫妥珠单抗联合全脑放射治疗II期临床试验的初步结果，用于诊断为晚期非小细胞肺癌不可切除的脑转移患者

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2008年第12期|共2页
作者
A.Macias; E.Neninger; E.Santiesteban; J.Figueredo; A.Hernandez; F.Aguirre; N.Aguilera; T.Crombet;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
入库时间 2022-08-18 18:38:24

相似文献

外文文献
中文文献
专利

1. 505 POSTER Preliminary results of a phase II clinical trial of the anti EGFR monoclonal antibody Nimotuzumab in combination with whole brain radiation therapy in patients diagnosed with advanced non-small cell lung cancer tumors unresectable brain metastases [J] . A.Macias, E.Neninger, E.Santiesteban, European Journal of Cancer Supplements . 2008,第12期

机译：505 POSTER抗EGFR单克隆抗体尼莫妥珠单抗联合全脑放射治疗II期临床试验的初步结果，用于诊断为晚期非小细胞肺癌不可切除的脑转移患者
2. Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy. [J] . Bebb G, Smith C, Rorke S, Cancer chemotherapy and pharmacology. . 2011,第4期

机译：在被诊断患有IIb，III或IV期非小细胞肺癌且不适合根治性治疗的加拿大患者中，抗EGFR单克隆抗体nimotuzumab并发外部胸腔放疗的I期临床试验。
3. Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy [J] . Gwyn Bebb, Colum Smith, Stewart Rorke, Cancer Chemotherapy and Pharmacology . 2011,第4期

机译：抗EGFR单克隆抗体尼莫妥单抗联合并发外部胸腔放疗的I期临床试验在加拿大诊断为IIb，III或IV期非小细胞肺癌且不适合根治性治疗的患者中
4. Photodynamic therapy stimulates anti-tumor immune response in mouse models: the role of regulatory T-cells, anti-tumor antibodies, and immune attack on brain metastases [C] . Fatma Vatansever, Masayoshi Kawakubo, Hoon Chung, Biophotonics and immune responses VIII . 2013

机译：光动力疗法在小鼠模型中刺激抗肿瘤免疫反应：调节性T细胞，抗肿瘤抗体的作用以及对脑转移瘤的免疫攻击
5. A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy [O] . Matthew A. Gubens, Jody C. Chuang, Wallace Akerley, 2018

机译：在接受贝伐单抗和培美曲塞作为二线治疗的两项II期临床试验中对脑转移稳定的晚期非鳞状非小细胞肺癌患者进行了汇总分析
6. P3-023: Preliminary results of an escalating dose phase I /II clinical trial of the anti EGFR monoclonal antibody nimotuzumab in combination with external radiotherapy in patients diagnosed with stage IIB, III or IV NSCLC unsuitable for radical therapy [O] . Bebb Gwyn, Smith Colum, ORourke K, 2007

机译：P3-023：在诊断为不适合根治性治疗的IIB，III或IV期NSCLC患者中，抗EGFR单克隆抗体尼莫妥珠单抗联合外部放射疗法的剂量递增的I / II期临床试验的初步结果

505 POSTER Preliminary results of a phase II clinical trial of the anti EGFR monoclonal antibody Nimotuzumab in combination with whole brain radiation therapy in patients diagnosed with advanced non-small cell lung cancer tumors unresectable brain metastases

著录项

相似文献

相关主题

期刊订阅